-
Mashup Score: 2
PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups. Here we report the final prespecified overall survival analysis.
Source: The LancetCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
Co-inhibition of poly(ADP-ribose) polymerase (PARP) and androgen receptor activity might result in antitumour efficacy irrespective of alterations in DNA damage repair genes involved in homologous recombination repair (HRR).
Source: The LancetCategories: Latest Headlines, UrologyTweet-
The third trial to report in this space was TALAPRO-2. Dr. Aggarwal presented the all-comers cohort from this trial at ASCO-GU this spring with the manuscript (highlighted here) subsequently published. Designed in much the same way as PROpel, this cohort of the TALAPRO-2 trial demonstrated significantly improved radiographic progression-free survival among all-comers with mCRPC receiving first-line treatment with talazoparib plus enzalutamide, compared to enzalutamide. To date, overall survival data remain immature.
-
-
Mashup Score: 4A pandemic playbook - 1 year(s) ago
Tedros Adhanom Ghebreyesus, the WHO Director-General, declared an end to over two years of COVID-19 pandemic’s emergency state in May 2023.
Source: The LancetCategories: Infectious Disease, Latest HeadlinesTweet-
A review of my book published in the Lancet.
-
-
Mashup Score: 2
There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors…
Source: The LancetCategories: Hem/Onc News and Journals, Hem/Oncs, Latest HeadlinesTweet-
Treatment options in metastatic colorectal cancer are limited in later lines of therapy. The FRESCO-2 study suggests that fruquitinib, an oral small molecule VEGFR inhibitor may be an option. What remains to be answered is if the improved OS benefit of 2.6 months is worth the cost in an appropriate QALY analysis.
-
-
Mashup Score: 0
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes.
Source: The LancetCategories: Hem/Onc News and Journals, Hem/Oncs, Latest HeadlinesTweet-
The TRANSCEND CLL 004 trial represents the most promising data of CAR T-cell therapy - liso-cel - in chronic lymphocytic leukemia (CLL), a disease where CAR T therapy has been particularly challenging due to impaired T-cell fitness. Only 18% of patients achieved complete remission, while another 29% achieved partial remission, although many of these responding patients seemed to show durable responses. The future of CAR T-cells in CLL remains uncertain. The trial was simultaneously published in The Lancet.
-
-
Mashup Score: 18
Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes.
Source: The LancetCategories: Expert Picks, Latest HeadlinesTweet-
TRANSCEND CLL 004 Liso-cel for R/R CLL presented at #ASCO23 lymphoma session & published in @TheLancet today: https://thelancet.com/journals/lancet/article/PIIS0140-6736(23)01052-8/fulltext ORR: 47% CRR 18% (PR 29%) Interestingly uMRD 59%, as there were patients who had stable disease by response criteria but uMRD #lymsm
-
-
Mashup Score: 2Punishing the tortured: criminalisation of suicide - 2 year(s) ago
Providing care and treatment for people with suicidal ideas, rather than subjecting them to a criminal process, seems intuitively humane and appropriate. And yet, in more than 20 countries, suicide and attempted suicide remain an offence punishable by imprisonment and fines for those who survive, and financial penalties for the families of those who do not. The continuation of laws against…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The Lancet and @TheLancetPsych have published recent content about the decriminalisation of suicide as a global imperative—read them below. Editorial: https://t.co/a5B4VLBBTl Comment: https://t.co/V7OwtQ0vUE
-
-
Mashup Score: 2Offline: How to fail well in global health - 2 year(s) ago
I am an expert in how to destroy global health initiatives. It is a peculiar fact that I have been an intimate witness to the demise of three promising organisations that sought to advance health in low-income settings—the Global Forum for Health Research, the Health Metrics Network, and the independent Expert Review Group on Information and Accountability for Women’s and Children’s Health…
Source: The LancetCategories: Infectious Disease, Latest HeadlinesTweet-
Lancet Offline: How to fail well in global health - five uncomfortable facts to keep you alert 💰🌟 https://t.co/tZeWWoo4Er https://t.co/6LCe45PFBQ
-
-
Mashup Score: 6Acute myeloid leukaemia - 2 year(s) ago
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
While the number of deaths (80,000 per year) caused by Acute myeloid leukaemia are expected to double, progress in treatment is occurring at an unprecedented pace. A new Seminar summarises current diagnostics, evolving treatments, and emerging research: https://t.co/CvDoZesibx
-
-
Mashup Score: 1
A recent Editorial1 pointed out that the National Health Service (NHS) in the UK is facing its most crucial moment since its inception due to a combination of chronic and acute problems, including underinvestment, understaffing, burnout among staff, and increasing demand for services. The inclination to believe that the current NHS model is unsustainable and needs radical change is misguided when…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New Correspondence—Addressing a potential crisis in the Italian National Health System: https://t.co/PxYJ4wPohI
-
This past month, we saw the publication of the final, pre-specified analysis of the PROpel study, assessing abiraterone and olaparib in combination. This study was the first to be presented and published and has led the push of evidence in this disease space. This analysis showed that, in the all-comer population, overall survival was not significantly different between patients receiving abiraterone and olaparib in combination compared to abiraterone alone as first-line mCRPC treatment. These data clearly influenced the FDAs approval in a biomarker driven approach.